The endonuclease EEPD1 mediates synthetic lethality in RAD52-depleted BRCA1 mutant breast cancer cells by Hromas, Robert et al.
RESEARCH ARTICLE Open Access
The endonuclease EEPD1 mediates
synthetic lethality in RAD52-depleted
BRCA1 mutant breast cancer cells
Robert Hromas1* , Hyun-Suk Kim2, Gurjit Sidhu1, Elizabeth Williamson1, Aruna Jaiswal1, Taylor A. Totterdale1,
Jocelyn Nole1, Suk-Hee Lee2, Jac A. Nickoloff3 and Kimi Y. Kong1*
Abstract
Background: Proper repair and restart of stressed replication forks requires intact homologous recombination (HR).
HR at stressed replication forks can be initiated by the 5′ endonuclease EEPD1, which cleaves the stalled replication
fork. Inherited or acquired defects in HR, such as mutations in breast cancer susceptibility protein-1 (BRCA1) or
BRCA2, predispose to cancer, including breast and ovarian cancers. In order for these HR-deficient tumor cells to
proliferate, they become addicted to a bypass replication fork repair pathway mediated by radiation repair
protein 52 (RAD52). Depleting RAD52 can cause synthetic lethality in BRCA1/2 mutant cancers by an unknown
molecular mechanism.
Methods: We hypothesized that cleavage of stressed replication forks by EEPD1 generates a fork repair intermediate
that is toxic when HR-deficient cells cannot complete repair with the RAD52 bypass pathway. To test this hypothesis,
we applied cell survival assays, immunofluorescence staining, DNA fiber and western blot analyses to look at the
correlation between cell survival and genome integrity in control, EEPD1, RAD52 and EEPD1/RAD52 co-depletion
BRCA1-deficient breast cancer cells.
Results: Our data show that depletion of EEPD1 suppresses synthetic lethality, genome instability, mitotic catastrophe,
and hypersensitivity to stress of replication of RAD52-depleted, BRCA1 mutant breast cancer cells. Without HR and the
RAD52-dependent backup pathway, the BRCA1 mutant cancer cells depleted of EEPD1 skew to the alternative
non-homologous end-joining DNA repair pathway for survival.
Conclusion: This study indicates that the mechanism of synthetic lethality in RAD52-depleted BRCA1 mutant
cancer cells depends on the endonuclease EEPD1. The data imply that EEPD1 cleavage of stressed replication
forks may result in a toxic intermediate when replication fork repair cannot be completed.
Keywords: Homologous recombination, Replication stress, Non-homologous end joining, synthetic lethality,
BRCA1, Breast cancer
Background
DNA replication does not proceed in a continuous man-
ner, but stalls and restarts at sites of DNA damage [1–3].
DNA damage occurs continuously from both endogenous
and exogenous sources [1–3]. Replication stress occurs
when the rate of proliferation overtakes the clearance of
the DNA damage ahead of progressing replication forks
[1–3]. Cancer cells experience high levels of replication
stress. Thus, efficient restart of stalled or collapsed replica-
tion forks is critical to their survival, particularly in
response to common cancer therapeutics [4, 5]. Radiation
repair protein 51 (RAD51)-dependent homologous re-
combination (HR) is the canonical repair and restart path-
way for stalled replications forks [6–9]. HR is best
characterized for the repair of DNA double-strand breaks
(DSBs). HR is mediated by a litany of components that are
regulated by breast cancer susceptibility protein-1
(BRCA1), which promotes the initial step in HR, 5′ end
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resection to create 3′ single-stranded (SS) DNA.
BRCA2 then loads RAD51 onto this SS DNA to
catalyze strand invasion into homologous sequences
(typically the sister chromatid) creating heteroduplex
DNA intermediates [2, 7, 8, 10]. After the invading
strand re-initiates DNA replication, HR intermediates
such as Holliday junctions are resolved by Holliday
junction 5′ flap endonuclease (GEN1) or MUS81
structure-specific endonuclease subunit (MUS81), with
SLX4 structure-specific endonuclease subunit (SLX4)
serving as a scaffold [11–13].
HR repair of stressed replication forks also requires 5′
end resection as an initial step. This 5′ end resection
needs a free DNA double strand (DS) end structure for
the 5′ exonuclease activity in end resection. There are
two ways to create this DS end: fork reversal to a
chicken foot structure, or fork cleavage by a structure-
specific nuclease [14–16]. We previously reported that
the 5′ endonuclease EEPD1 could cleave stalled replica-
tion forks, initiate EXO1-mediated 5′ end resection, and
promote repair of HR replication forks independent of
BRCA1 [17–19]. However, BRCA1/2-mutant cancer cells
lack HR, and how these cells repair stalled replication
forks has been an unresolved issue. Several reports point
to RAD52 in fulfilling this function. In yeast, Rad52
plays an essential role in HR, including HR-mediated re-
start of collapsed replication forks [20–22]. However,
early studies suggested that in mammals the essential
roles for RAD52 in HR have been supplanted [23], per-
haps by BRCA2. We reported that human RAD52 foci
appear 4–6 h after exposure to ionizing radiation, long
after RAD51 foci appear, and we proposed that these
late-appearing foci reflected a conserved role for human
RAD52 in HR-mediated repair of collapsed replication
forks [24]. This model was supported by a subsequent
study showing that DSBs arising many hours after ex-
posure to ionizing radiation were replication-dependent
and repaired by HR [25]. In a separate line of investiga-
tion, RAD52 was identified as essential for viability of
cancer cells with defects in various HR proteins includ-
ing BRCA1, BRCA2, and partner and localizer of BRCA2
(PALB2) [23, 26, 27]. Together, these results suggest that
RAD52 functions in a backup HR pathway independent
of BRCA1/2, in which RAD52 loads RAD51 onto SS
DNA for HR repair at stalled forks [26–29]. RAD51 then
promotes the strand invasion required to complete HR
repair and replication fork restart [26–28].
However, RAD52 still needs an end-resected 3′ SS
upon which to load RAD51. Thus, 5′ end resection is
still required for the backup pathway, yet this is prob-
lematic if BRCA1 is not functional, because BRCA1 pro-
motes resection [30–32]. Since EEPD1 can operate
independently of BRCA1 to initiate EXO1-mediated 5′
end resection after replication fork stalling [18, 19], this
suggests that in the absence of functional BRCA1,
EEPD1 can initiate the 5′ end resection needed for gen-
eration of the 3′ SS DNA required for RAD51 loading.
Repairing stressed replication forks is a high priority for
the cell. If stressed replication forks are not repaired in
timely manner, they may convert into toxic structures that
make fork restart difficult [3, 9, 12, 13, 33], leading to mi-
totic catastrophe as demonstrated by nuclear abnormal-
ities, including nuclear bridges and micronuclei. These
nuclear abnormalities can arise from non-homologous
end joining (NHEJ)-mediated fusion of free DS ends at
unrepaired replication forks [3, 34–36]. Unbalanced
chromosomal fusions can result in chromosomes without
centromeres, which are retained as micronuclei after mi-
tosis, and chromosomes with two centromeres, which
form chromosomal bridges between daughter cells during
mitosis [36, 37]. Since BRCA1/2 mutant cancer cells use
RAD52 as an escape pathway for HR-mediated replication
fork repair and restart, depleting RAD52 causes mitotic
catastrophe and synthetic lethality in these cells. Thus,
RAD52 has emerged as a target of interest for pharma-
ceutical intervention for novel synthetic lethal treatment
strategies for BRCA1/2 mutant cancers [38–40]. However,
the molecular mechanism by which RAD52 deficiency
causes synthetic lethality of BRCA1/2 mutant cancer cells
has not been identified [26, 27, 29].
In this study we show that EEPD1 is required for death
of BRCA1 mutant breast cancer cells that have been de-
pleted of RAD52. Specifically we show that depletion of
EEPD1 rescues the synthetic lethality of RAD52-depleted,
BRCA1 mutant breast cancer cells. Co-depletion of
EEPD1 with RAD52 promotes restart of stalled replication
forks, and suppresses chromosome aberrations and mi-
totic catastrophe compared to RAD52 depletion alone.
These results suggest that EEPD1 may play a role in gen-
erating a toxic replication fork intermediate that leads to
mitotic catastrophe.
Methods
Cell culture, transfection, and survival assays
EEPD1 and/or RAD52 were selectively depleted using
small interfering RNA (siRNA) transient transfection (Li-
pofectamine RNAiMAX transfection Reagent, Life Tech-
nologies). SMARTpool ON-TARGETplus Non-target pool
(SiRNA control) (D-001810-10-20), EEPD1 SiRNA (L-
014641-01-0020), RAD52 SiRNA (L-011760-00-0010), X-
ray repair cross-complementing protein (XRCC4) siRNA
(L-004494-00-0005), DNA ligase IV (LIG4) (L-004254-00-
0005), polymerase theta (POLQ) siRNA (L-015180-01-
0010) and BRCA1 siRNA (L-003461-00-0005) were pur-
chased from Dhamarcon RNAi Technologies (Pittsburgh,
PA, USA). Briefly, the day prior to transfection, cancer
cells (MDA-MB-436, SUM149PT and MCF7) were plated
at a density of 1.4 × 105 per well. Transfection reagents
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were prepared by mixing 6 μl of RNAiMAX/250 μl Opti-
MEM (Life Technologies) to 50 nM of siRNA/250 μl
Opti-MEM at room temperature (RT) for 20 min before
adding to cells. Between 4 h and 6 h after transfection,
0.5 ml of fresh medium was added to each well for all cell
types except MCF7. Instead of 50 nM siRNA, 10 nM of
siRNA was used in all MCF7 transfections [27]. Cells were
harvested at 2 days post-transfection for clonal colony for-
mation (survival), western analysis, immunofluorescence
or other assays. All experiments were performed at least
three times in triplicate (n > 9).
Clonal survival was determined by seeding transfected
cells (800 MDA-MB-436 (+ or -/-), 1000 MCF7 or 1000
SUM149PT) per well of a 6-well plate and cells were
allowed to expand for 10–12 days (MDA-MB-436
BRCA1+, SUM149PT) or 14–18 days (MDA-MB-436
BRCA1-/-, MCF7). Cells were then rinsed with 1 × PBS,
fixed with 1% formaldehyde for 10 min and stained with
0.1% crystal violet before counting. Colonies with > 50
cells were counted as a surviving clone. For hydroxyurea
(HU) treatment (H8627) (Sigma, St. Louis, MO, USA),
cells were treated with 10 mM HU overnight at the 48-h
post-transfection time point and subsequently harvested
for colony formation assay as described. The unpaired
Student t test was used for all statistical analysis, unless
otherwise indicated.
MDA-MB-436 breast cancer cells (BRCA1 mutant (-/-)
or replete (+)) (ATCC, Manassas, VA, USA) and MCF7
(ATCC) were cultured in D-MEM (Life Technologies,
Carlsbad, CA, USA) supplemented with 10% fetal bovine
serum (Hyclone) and 1% penicillin and streptomycin
(Life Technologies).
SUM149PT BRCA1-/- breast cancer cells (Asterand Bio-
science, Detroit, MI, USA) were cultured in Ham’s F-12
medium (Invitrogen) supplemented with 5% heat inacti-
vated FBS (Hyclone), 10 mM HEPES (Invitrogen), 1 μg/ml
hydrocortisone (Sigma) and 5 μg/ml insulin (Sigma).
Western blot analysis
Protein expression of EEPD1, RAD52, DNA ligase 4
(LIG4), XRCC4, POLQ, BRCA1, BRCA2, and the consti-
tutively expressed cyclophilin B was monitored by stand-
ard western blotting. EEPD1 expression was detected by
a custom-produced mouse polyclonal antibody to
EEPD1 protein (Interdisciplinary Center for Biotechnol-
ogy Research Core Facility, UF, Gainesville, FL, USA)
[19, 41]. RAD52, LIG4, BRCA1, and BRCA2 antibodies
were purchased from Santa Cruz Biotech (sc-8350, sc-
365341, sc-271299, sc-6954 and sc-1818). POLQ and
XRCC4 antibodies were purchased from ThermoFisher
Scientific (PA5-39885 and PA5-27104). Cyclophilin B
antibodies were purchased from Abcam (ab178397)
(Cambridge, MA, USA). Secondary antibodies used for
enhanced chemiluminescence (EC) detection were ECL
Rabbit IgG, HRP-linked Whole Ab (NA934-1ML), HRP-
conjugated mouse secondary antibody (NA931-1ML)
(Thermo Fisher Scientific, Waltham, MA, USA) and
HRP-conjugated goat IgG (sc-2020, Santa Cruz Biotec).
SuperSignal West Pico Chemiluminescent Substrate
(ECL) (34078) and High Performance Chemilumines-
cence film; Amersham Hyperfilm ECL (45001508) were
purchased from Thermo Fisher Scientific.
Expression levels of proteins involved in the ATM/
ATR DNA damage signaling pathway were examined
using ataxia-telangiectasia mutated kinase (ATM)
(2873), p-ATM (5883), ATM-related and Rad3-related
kinase (ATR) (2790), Checkpoint kinase 1 (Chk1) (2341),
p-Chk1 (2348), Chk2 (2662) and p-Chk2 (2662) anti-
bodies from Cell Signaling Technology (Danvers, MA,
USA), p-ATR (GTX128145) antibodies from GeneTex
(Irvine, CA, USA), replication protein A 32 (RPA32)
(A300-244A) and p-RPA32 (A300-245A) antibodies
from Bethyl Laboratories (Montgomery, TX, USA).
Immunofluorescence
Immunofluorescence foci assays were performed as we
previously described with minor modifications [19]. In
brief, MDA-MB-436 BRCA1-/- cells were cultured on
coverslips followed by siRNA transfection. At the prede-
termined time points (1, 2, 3, or 4 days post transfec-
tion), cells were fixed with 1% formaldehyde for 10 min
at ambient temperature, rinsed with 1 × PBS, incubated
with methanol for > 5 min at − 20 °C, rinsed with 1 ×
PBS and permeabalized with 0.1% Triton-X for 3 min
before incubation with phosphorylated histone 2A family
member X (γH2AX) antibodies (05-636) (1:200) (Milli-
pore, Temecula, CA, USA) at 4 °C overnight. The cells
were then rinsed with 1 × PBS multiple times. Secondary
antibodies (Goat anti-Mouse IgG, Alexa Fluor® 568 con-
jugate, A11004) (1:400) (Thermo Fisher) were added to
the cells at ambient temperature and protected from
light for 1 h. After washing thrice with 1 × PBS, cover-
slips were mounted in an anti-fade solution containing
4',6-diamidino-2-phenylindole (DAPI).
All samples were analyzed using either a Zeiss fluores-
cence microscope (Axiovert 200 M) (Carl Zeiss Micros-
copy, LLC, Thornwood, NY, USA) or a Leica TCS SP5
confocal scanning microscope (Leica Microsystems,
Exton, PA, USA). Immunofluorescence images were taken
using a Hamamatsu ORCA-ER digital camera (Hamama-
tsu Photonics K.K, Bridgewater, NJ, USA) and processed
by Zeiss Axiovision Release 4.6 software. Images from
confocal microscopy were processed by Leica LAS AF im-
aging software. Cells with ≥ 5 foci were scored as positive.
Photomicrographs of distinct cell populations were taken
at equal magnifications and equal fluorescence intensities.
To assess nuclear structural abnormalities (micronuclei
and post-mitotic bridging), MDA-MB-436 BRCA1-/- cells,
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with or without EEPD1 and/or RAD52 depletion, were
fixed as described above, and stained with 300 nM DAPI
(Beckman) in PBS for 5 min. After washing with PBS, cov-
erslips were mounted in anti-fade solution and analyzed
using confocal microscopy. Each immunofluorescence
assay was performed at least three times.
Analysis of chromosome breaks
Cytogenetic analysis of chromosome breaks was per-
formed as we described with minor modifications [19].
Briefly, 24 h prior to transfection, 1.6 × 105 cells were
plated into wells containing 1.5- mm coverslips. Cells
were transfected with control, EEPD1, and/or RAD52
siRNA using Lipofectamine RNAiMAX reagent as de-
scribed. After 48 h, cells were treated with Colcemid
(final concentration of 0.1 ug/ml) (Sigma) for 2 h at 37 °
C, 5% CO2. After 2 h, cells were treated with 75 mM
KCl at 37 °C, 5% CO2. After 15 min, 0.1 volume of fixa-
tive (methanol/acetic acid 3:1) was added to the KCL for
a few seconds and the supernatant was aspirated and re-
placed by 1 ml fresh fixative for 5 min at room
temperature. The step was repeated two more times.
Coverslips were then left for air drying and cells were
rehydrated with PBS for 5 minutes and stained for the
Giemsa Stain (Karyomax Giemsa Stain, 10092) (Gibco,
Carlsbad, CA, USA) for 5 min at RT. The coverslips
were rinsed three times with deionized water,
mounted and examined with a × 63 objective con-
nected to a Zeiss Axiovert 200 M microscope. At
least 50 metaphases were analyzed for chromatid
breaks in each cell preparation. Data were collected
from three separate experiments.
DNA fiber analysis of replication fork repair and restart
DNA fiber analysis for measuring stalled replication fork
repair and restart was performed as we previously de-
scribed [30, 31]. Briefly, 600,000 of MDA MB 436
BRCA1-/- cells were incubated overnight at 37 °C in 6-
well plates, then 20 mM iodo-deoxyuridine (IdU) was
added to the growth medium and incubated for 20 min
at 37 °C. The IdU medium was removed and cells
washed in fresh medium. Cells were then treated with
5 mM HU for 120 min or mock-treated. The HU-
containing medium was replaced with fresh medium
containing 100 mM chloro-deoxyuridine (CldU). Cells
were then incubated for varying times at 37 °C. The
CidU medium was removed, cells harvested, resus-
pended in PBS, and ∼ 1000 cells were transferred to a
positively charged microscope slide (Superfrost/Plus,
Daigger), and processed for DNA fiber analysis as we de-
scribed previously [32]. Slides were mounted in Perma-
Fluor aqueous, self-sealing mounting medium (Thermo
Scientific), and DNA fibers were visualized using an
Olympus FV1000D confocal scanning microscope
(Olympus America Inc., Center Valley, PA, USA). Im-
ages were analyzed using ImageJ software.
DNA resection at stalled replication forks
Single-label DNA fiber end-resection analysis was carried
out as previously described with some modifications [16,
42]. Briefly, MDA-MB-436 BRCA1 mutant cells trans-
fected with the indicated siRNA were grown in 6-well
dishes (2 × 105 cells/well), and then 20 μM IdU was added
to the growth medium and incubated for 45 min at 37 °C.
After washing with fresh medium, cells were treated with
5 mM hydroxyurea for 0 or 10 h at 37 °C. Cells were har-
vested and suspended in PBS, and 1000 cells were trans-
ferred to a positively charged microscope slide and
processed for DNA fiber analysis as we described previ-
ously [43]. Slides were mounted in PermaFluor aqueous,
self-sealing mounting medium (Thermo Scientific), and
DNA fibers were visualized using a confocal microscope
(Olympus, FV1000D, × 63 oil immersion objective). Im-
ages were analyzed using ImageJ software.
Results
Depletion of EEPD1 promotes survival in BRCA1-mutated
and RAD52-depleted breast cancer cells
MDA-MB-436 BRCA1-/- breast cancer cells were de-
pleted of EEPD1 and/or RAD52 using siRNA. Consistent
with previous studies [26, 27], RAD52 depletion in
BRCA1-/- cells reduced cell viability threefold compared
to control siRNA-transfected cells, as demonstrated by
reduced colony formation units (CFUs) (Fig. 1a–d).
RAD52 depletion did not affect clonal cell survival in
MDA-MD-436 BRCA1+ breast cancer cells (Additional
file 1: Figure S1A − C). When we depleted BRCA1 in
MDA-MB-436 BRCA1+ cells, it re-sensitized the cells to
RAD52 depletion (Additional file 1: Figure S1D–F). De-
pletion of EEPD1 in BRCA1-/- cells also reduced clonal
cell survival twofold, consistent with its known role in
replication stress repair [19]. Interestingly, depletion of
both RAD52 and EEPD1 together fully restored clonal
cell viability to levels indistinguishable from control cells
(Fig. 1a–c). We repeated the clonal survival experiments
with a second BRCA1 mutant breast cancer cell line,
SUM149PT [44]. When depleted of RAD52, synthetic le-
thality was observed in these BRCA1 mutant cells as
well (Additional file 2: Figure S2). When EEPD1 and
RAD52 were co-depleted, clonal cell viability was re-
stored to levels that were comparable to control cells
(Additional file 2: Figure S2).
Next, we created HR-deficient MCF7 breast cancer
cells by transiently depleting BRCA1. We found that
BRCA1-deficient MCF7 cells were highly sensitive to
RAD52 depletion, consistent with a previous report
(Additional file 3: Figure S3A–C) [27]. Interestingly, our
data showed that, unlike BRCA1 mutant MDA-MB-436
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and SUM149PT cancer cells, BRCA1-depleted MCF7
cancer cells were not sensitive to EEPD1 depletion
(Fig. 1, Additional file 2: Figure S2 and Additional file 3:
Figure S3D–F). However, co-depletion of EEPD1 and
RAD52 did promote clonal cell viability in BRCA1-
suppressed MCF7 cells (Additional file 3: Figure S3D–
Fig. 1 Depletion of endonuclease/exonuclease/phosphatase family domain-containing-1 (EEPD1) promotes survival in breast cancer susceptibility
protein-1 (BRCA1)-mutated and radiation repair protein 52 (RAD52)-deficient breast cancer cells. MDA-MB-436 BRCA1-/- cells were transfected with
control, EEPD1 and/or RAD52 siRNA for 48 h and then cells were plated for colony formation unit (CFU) clonal survival assays. a Western blot analysis
of EEPD1 and RAD52 depletion with cyclophilin B (CypB) as a loading control. b Representative images of clonal colony formation for each condition
after 14 days. c Quantitative analysis of colony formation under unstressed (no hydroxyurea (HU)) or stress conditions (10 mM hydroxyurea
(HU) overnight). d Relative survival data from c normalized by unstressed scrambled control siRNA. Each experiment was performed more than
three distinct times in triplicate. For this and all subsequent figures, *p < 0.05, **p < 0.01, ***p < 0.001
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F). Thus, the cell death seen in BRCA1-deficient breast
cancer cells with RAD52 depletion requires the HR
endonuclease EEPD1.
We also examined survival of MDA-MB-436 BRCA1-/-
cancer cells after 18 h treatment with 10 mM HU
(Fig. 1c, d), which causes replication fork stalling and
collapse [11]. As expected, BRCA1-/- breast cancer cells
were sensitive to HU (control siRNA), and this was exac-
erbated by RAD52 depletion (Fig. 1c, d). EEPD1 deple-
tion in BRCA1-proficient cells causes sensitivity to HU
[19] and EEPD1 depletion in BRCA1-/- cells also seemed
to cause further sensitization to HU (Fig. 1c, d). Import-
antly, co-depletion of RAD52 and EEPD1 decreased HU
sensitivity of BRCA1-/- cells. In fact, the doubly depleted
cells were significantly more resistant to HU than
control cells (Fig. 1c, d).
RAD52 depletion increases genome instability in
BRCA1-deficient breast cancer cells
Previous studies found that RAD52 depletion in BRCA2-
defective breast cancer cells is associated with spontan-
eous and radiation-induced chromosomal aberrations
[26]. We depleted RAD52 in MDA-MB-436 BRCA1-/-
breast cancer cells, stained nuclei with DAPI and mea-
sured nuclear abnormalities. We assessed retained chro-
mosomes, seen as micronuclei, and mis-segregated
chromosomes, seen as post-mitotic bridges [36, 37]. We
found that a significantly higher fraction of RAD52-
depleted BRCA1 mutant cells had micronuclei compared
to control cells (Fig. 2a, b). RAD52 depletion also sig-
nificantly increased the frequency of bridges in the
BRCA1 mutant cells (Fig. 2a, c). Chromosomal breaks
are specifically associated with unrepaired replication
stress [45], and can be quantified using metaphase
analysis. Metaphase analysis also showed a marked in-
crease in chromosomal breaks when RAD52 was de-
pleted in BRCA1 mutant cells (Fig. 3d, e).
The synthetic lethality of combined RAD52 and
BRCA1/2 deficiency is thought to reflect inefficient re-
pair and restart of stressed replication forks, resulting in
their collapse [26, 27]. These collapsed forks are marked
by γ-H2AX, reflecting chromatin changes adjacent to
the unrepaired DS ends seen in collapsed forks [11].
Consistent with this model, depletion of RAD52 in
BRCA1-deficient breast cancer cells increased γ-H2AX
nuclear foci compared to control cells (Fig. 3a, b). The
DNA damage signaling kinases ATR and ATM are acti-
vated by phosphorylation in the DNA damage response
[46]. Analysis of phosphorylated ATR and ATM proteins
and their downstream signal transducers, phosphory-
lated CHK1 and CHK2, confirmed that these DNA dam-
age signaling pathways were indeed highly activated in
RAD52-depleted BRCA1- cells (Fig. 3c), consistent with
replication fork collapse.
EEPD1 depletion restores genome stability in
RAD52-depleted BRCA1 mutant breast cancer cells
When EEPD1 was co-depleted with RAD52 in BRCA1-/-
breast cancer cells, levels of micronuclei and nuclear brid-
ges were reduced to levels comparable to those seen in
control cells (Fig. 2b, c). In addition, compared to RAD52
depletion alone, double depletion of EEPD1 and RAD52
resulted in fewer γ-H2AX-positive cells (Fig. 3a). Meta-
phase analysis also found that co-depleting EEPD1 with
RAD52 reduced chromosome breaks in BRCA1 mutant
cells back to control levels (Figs. 2 and 3). For each of the
genome instability endpoints (nuclear abnormalities,
chromosome breaks, and γ-H2AX-positive cells), levels in
BRCA1-deficient cells with EEPD1/RAD52 double deple-
tion were comparable to levels of control cells. Together,
these results indicate that the genome instability caused
by depleting RAD52 in BRCA1-/- cells is dependent on
the HR endonuclease EEPD1.
EEPD1 depletion rescues stressed replication forks in
RAD52-depleted BRCA1-deficient breast cancer cells
We next used DNA fiber analysis to measure repair and
restart of stressed replication forks in either mock-
treated or HU-treated cells for 20 or 40 min after release
from HU (Fig. 4a). DNA fibers were analyzed for unre-
paired forks (red IdU label only), repaired and restarted
forks (both red IdU and green CldU label on a single
fiber), and newly originated forks (green CIdU label
only). As shown in Fig. 4b–d, depletion of RAD52 in
BRCA1-/- cells increases the frequency of forks that fail
to restart, and this was apparent with 20 or 40 min re-
covery from HU replication stress. Depletion of EEPD1
also reduced fork restart, as reported previously [19], al-
beit to a lesser degree than RAD52 depletion in the
BRCA1-/- cancer cells. Double depletion of RAD52 and
EEPD1 partially restored fork restart to a level between
control and RAD52 depletion alone during the 20 and
40 min recovery periods.
When a replication fork stalls, replication recovery can
result from fork restart, or more rarely from activation of
nearby dormant replication origins [11, 19, 47]. RAD52
and/or EEPD1 depletion reduced new replication fork fir-
ing at 20 min recovery after HU replication stress (Fig. 4d).
After 40 min of recovery from HU removal, a significant
decrease in new forks was only seen with RAD52 deple-
tion alone, thus co-depletion of EEPD1 suppressed the ef-
fect of RAD52 depletion on new fork initiation. Thus,
RAD52 depletion in BRCA1-/- cells suppresses both fork
repair and restart and new fork initiation, and these effects
are suppressed by co-depletion of EEPD1.
We also measured IdU:CldU tract-length ratios, which
provides quantitative information about the extent of
replication recovery at forks that restarted. Under non-
stress conditions, IdU and CldU track lengths are
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approximately equal, giving an IdU:CldU ration of ~ 1.0,
which means that the stressed replication fork fully re-
covered to its baseline progression rate. As shown in the
top graph of Fig. 4e, unstressed BRCA1-/- cells displayed
a narrow distribution of IdU:CldU ratios centered
around 1.0, and this was unaffected by depletion of
RAD52 and/or EEPD1 (Fig. 4f, left panel). In cells
treated with HU between IdU and CldU pulses, broader
distributions with higher IdU:CldU ratios are observed
(Fig. 4e, bottom graph). Higher IdU:CIdU ratios reflect
inefficient replication recovery among stressed forks. In
this assay, inefficient replication fork recovery may re-
flect slower fork repair and/or slower progression upon
restart. Under HU stress conditions, EEPD1 depletion
slightly increased the average IdU:CldU ratio, whereas
RAD52 depletion increased the ratio by >2-fold
(Fig. 4f, right panel). Interestingly, the ratio with
double depletion of EEPD1 and RAD52 was similar to
that with EEPD1 depletion alone, indicating that the
defect in replication recovery caused by RAD52 de-
pletion in BRCA1-defective cells is largely suppressed
by co-depletion of EEPD1.
Stressed replication fork degradation can be measured
by single-label DNA fiber analysis [16, 42, 43]. Such deg-
radation of recently labeled DNA can be from normal end
resection initiating HR or from nuclease destruction of
collapsed replication forks [48–53]. We have previously
demonstrated that EEPD1 is essential for stressed fork
degradation from end resection in this assay [18, 41].
When we measured HU-stressed replication fork degrad-
ation in BRCA1 mutant breast cancer cells we found that
depleting RAD52 or EEPD1 led to less stressed replication
Fig. 2 Restoration of genome stability by endonuclease/exonuclease/phosphatase family domain-containing-1 (EEPD1) depletion in radiation repair
protein 52 (RAD52)-depleted breast cancer susceptibility protein-1 (BRCA1)-deficient breast cancer cells. MDA-MB-436 BRCA1-/- cells were depleted of
EEPD1 and/or RAD52, stained with 4',6-diamidino-2-phenylindole (DAPI) and analyzed for nuclear aberrations. a Representative photomicrographs.
White arrowheads indicate micronuclei and red arrowhead indicates a nuclear bridge. Quantitative analysis of cell population that carried micronuclei
(b) or nuclear bridges (c). Each data set was collected from five different × 40 fields from three distinct experiments. Mean ± SEM is shown. Scale = 25 uM
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Fig. 3 Genomic instability in radiation repair protein 52 (RAD52)-depleted breast cancer susceptibility protein-1 (BRCA1)-deficient breast cancer
cells. a Representation photomicrographs of immunofluorescence staining of DNA double strand break marker, phosphorylated histone 2A family
member X (γ-H2AX), showed various levels of nuclear foci formation in MDA- MB-436 BRCA1-/- cells with or without endonuclease/exonuclease/
phosphatase family domain-containing-1 (EEPD1) and/or RAD52 depletion. b Quantitative analysis of γ-H2Ax foci-positive (≥5 foci per cell) cell
population in each condition. Cells were counterstained with 4',6-diamidino-2-phenylindole (DAPI). Each set of data was collected from five different ×
40 fields from three distinct experiments. Mean + SEM is shown. Scale = 25 uM. c Western blot analysis of EEPD1, RAD52, phosphorylated
ataxia-telangiectasia mutated kinase (ATM) and Rad3-related kinase (p-ATR), ATR (total), phosphorylated checkpoint kinase 1 (p-CHK1),
CHK1 (total), p-ATM (phosphorylated), ATM (total), p-CHK2 (phosphorylated), CHK2 (total), phosphorylated p-replication protein A 32 kDa
subunit (p-RPA32), RPA32 (total) and cyclophilin B (CypB) as a loading control in EEPD1and/or RAD52 depleted cells. d Cytogenetics showing an increase
in chromosome breakage after RAD52 depletion in BRCA1-/- cells. Representative images of metaphases from each condition. Arrowhead indicates sites of
chromosome breakage. e Quantitation of chromosomal breakage in each condition, with mean ± SEM shown (three distinct experiments
with > 20 metaphases counted per experiment)
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Fig. 4 Endonuclease/exonuclease/phosphatase family domain-containing-1 (EEPD1) depletion rescues stressed replication forks in radiation repair
protein 52 (RAD52)-depleted breast cancer susceptibility protein-1 (BRCA1)-deficient breast cancer cells. DNA fiber analysis of stalled, restarted or
new forks in MDA-MB-436 BRCA1-/- cells transfected with control, EEPD1 and/or RAD52 siRNA. a Schematic diagram depicts steps for the DNA
fiber assay and representative images of DNA fibers from each condition. Forks prior to stress with hydroxyurea (HU) are stained red with
iodo-deoxyuridine (IdU), new forks after relieving stress are stained green with chloro-deoxyuridine (CldU). Quantitative analysis of stalled
(only red fibers) (b), restarted (red then green fibers) (c) and new forks (only green fibers) (d) after release from HU replication stress. e, f
Quantitative analysis of stalled versus restarted replication forks (IdU:CIdU) ratios under unstressed condition or stressed condition (5 mM
HU for 120 min). Three distinct experiments per condition (>121 fibers measured per condition for each experiment)
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fork degradation, but co-depletion of both restored deg-
radation to control levels (Additional file 4: Figure S4).
While depleting EEPD1 would result in decreased end re-
section, it is more likely that RAD52 depletion results in
stressed fork nuclease destruction [23, 26, 27].
BRCA1-deficient breast cancer cells depleted of both
EEPD1 and RAD52 rely on alternative non-homologous
end-joining pathway (aNHEJ) for survival
Our data confirm that synthetic lethality can be induced in
BRCA1-deficient breast cancer cells through depletion of
RAD52, possibly through the accumulation of a toxic fork
repair intermediate. However, when EEPD1 is also depleted
in the RAD52-depleted BRCA1-deficient breast cancer
cells, the synthetic lethality is completely abolished. To ad-
dress which escape pathway these EEPD1/RAD52 double-
depletion BRCA1-deficient cells rely on for survival, we
performed clonal cell survival assays with additional deple-
tion of either X-ray repair cross-complementing protein
(XRCC4) or DNA ligase IV (LIG4) to examine the classical
NHEJ (cNHEJ) pathway and POLQ to examine the alter-
native NHEJ pathway (aNHEJ) (Fig. 5).
When XRCC4 or LIG4 were depleted in the EEPD1/
RAD52 co-depleted BRCA1-deficient breast cancer cells,
no significant reduction in cell survival was observed
(Fig. 5c). In addition, an increase of ~ 30% in clonal cell
survival was observed in the EEPD1/RAD52/XRCC4
triple-depleted breast cancer cells compared to the
EEPD1/RAD52 co-depletion cells respectively (Fig. 5c).
This implies that the double-depleted EEPD1/RAD52
BRCA1 mutant cells do not rely on the cNHEJ pathway
for survival. We then investigated whether aNHEJ was
the escape pathway utilized by the EEPD1/RAD52 co-
depleted BRCA1-deficient cancer cells for survival. We
depleted POLQ, a DNA polymerase that promotes
aNHEJ [46, 54], in the EEPD1/RAD52 co-depleted
BRCA1-deficient cells. There was a reduction in cell sur-
vival in the EEPD1/RAD52/POLQ triple-depleted cells
when compared to EEPD1/RAD52 co-depleted cells
(Fig. 5c). This implies that the EEPD1/RAD52 co-
depleted cells use the aNHEJ pathway to repair their
stressed replication forks [55, 56].
We also repeated the cell survival assay with single de-
pletion of XRCC4, LIG4 or POLQ in the MDA-MB-436
BRCA1-/- cells for comparison (Additional file 5: Figure
S5). Little impact on cell survival was observed from
XRCC4 or LIG4 singly depleted cells (Additional file 5:
Figure S5), which was similar to the triple-depleted cells
(XRCC4/EEPD1/RAD52 or LIG4/EEPD1/RAD52) (Fig. 5).
When POLQ was depleted in the MDA-MB-436
BRCA1-/- cells, the level of synthetic lethality was also
comparable to the triple-depleted cells (POLQ/EEPD1/
RAD52) (Additional file 5: Figure S5 and Fig. 5).
Discussion
BRCA1 mutant or BRCA2 mutant malignancies rely on
RAD52 to repair stressed replication forks [26, 27, 29].
Depletion of RAD52 results in synthetic lethality of
these homologous recombination (HR)-deficient cancers
[26–29]. This study demonstrates that the synthetic le-
thality seen when RAD52 is depleted in BRCA1 mutant
breast cancer cells depends on the HR endonuclease
EEPD1. Previously, we have shown that EEPD1 nicks
stressed replication forks to initiate 5′ end resection,
which creates 3′ SS DNA for RAD51 loading to affect
HR repair of stalled forks [18, 19]. The fact that syn-
thetic lethality of RAD52-depleted BRCA1-deficient cells
can be suppressed by downregulating EEPD1 implies
that EEPD1 cleavage of stalled forks may create a toxic
fork repair intermediate that is lethal if repair is not
completed. In cells that lack BRCA1/2 and RAD52,
EEPD1 would cleave stressed replication forks to permit
5′ end resection, but those cells would not progress past
this repair intermediate. Repair would be arrested before
RAD51-dependent homology-mediated single-strand in-
vasion could occur. These cleaved replication forks
would have free DS ends that could produce chromo-
somal fusions mediated by tumor protein P53 binding
protein (53BP1)-dependent NHEJ [34, 35]. In BRCA1
mutant cancer cells, unrepaired replication forks can
generate chromosomal fusions, leading to chromosomal
instability and mitotic catastrophe [34–37]. Depleting
53BP1 rescues replication stress-induced chromosomal
instability in these cells [19, 34, 35]. Thus, one mechan-
ism of cell death in the RAD52-depleted BRCA1 mutant
cells could be chromosomal fusion of cleaved, but unre-
paired forks, resulting in mitotic catastrophe.
Interestingly, our study finds that depletion of XRCC4
or DNA ligase IV, key components in the cNHEJ repair
pathway, has little impact on cell viability in the MDA-
MB-436 BRCA1-/- cells (Fig. 5, Additional file 5: Figure
S5). In contrast, depletion of POLQ, a mediator of aNHEJ,
induces severe synthetic lethality in the BRCA1-/- cells
(Fig. 5, Additional file 5: Figure S5). These observations
are consistent with a previous report showing that
BRCA1-deficient cancer cells are dependent on the aNHEJ
pathway for replication [46]. Our study shows that MDA-
MB-436 BRCA1-/- cells rely heavily for survival upon the
RAD52 recombination repair pathway, or if that fails, on
the aNHEJ pathway (Fig. 1, Additional file 5: Figure S5).
This implies that the RAD52 alternative HR repair path-
way is effectively arrested in the co-depleted BRCA1 mu-
tant cells, whereas the aNHEJ repair pathway remains
active. In addition, unlike their ability to restore chromo-
somal integrity and replication efficiency (Figs. 2, 3 and 4),
co-depletion of EEPD1 and RAD52 in BRCA1-/- cells only
has a moderate effect on DNA end-resection (Additional
file 5: Figure S5). This is not surprising, since EEPD1
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depletion would arrest replication fork repair before 5′
end resection, and repair of the fork might default to
aNHEJ. POLQ-mediated aNHEJ typically does not com-
pete with HR repair of stressed replication forks, probably
because it is non-conservative, and the cell would desig-
nate it as a backup for conservative HR repair to protect
its genome [55–57].
Repairing and restarting stressed replication forks is one
of the highest priorities for any cell. Indeed, there is a
great deal of evidence that cells will bypass DNA lesions
to maintain replication rates [41, 47]. We and others have
found that even delaying fork repair by 15–30 min can
have lethal consequences [17, 19, 35, 47]. The data pre-
sented here suggest a model in which an EEPD1-cleaved
replication fork repair intermediate is rapidly recognized
by the cell as toxic, and in the absence of BRCA1 and
RAD52, the free DS ends are shunted toward the aNHEJ
repair pathway. Without the toxic EEPD1-cleaved fork re-
pair intermediate, aNHEJ can repair the stressed replica-
tion fork and permit the RAD51-depleted BRCA1 mutant
cell to survive [55–57]. This implies a hierarchy of
replication fork repair pathways, with classical HR as
favored, but in the absence of BRCA1/2, the cell
chooses the RAD52 backup HR pathway [26–29].
When cells lack both classical HR and the RAD52-
mediated backup pathway, they choose aNHEJ to re-
pair stalled replication forks [13, 14, 55–57]. This
may also explain why depleting both EEPD1 and
RAD52 improves the survival of BRCA1 mutant cells
after HU replication stress (Fig. 1c, d); this would
force cells away from the RAD52 pathway to the
more efficient but less conservative aNHEJ pathway.
Fig. 5 Breast cancer susceptibility protein-1 (BRCA1)-deficient breast cancer cells depleted of both EEPD1 and RAD52 rely on alternative non-homologous
end-joining pathway (aNHEJ) for survival. MDA-MB-436 BRCA1-/- cells were transfected with control, endonuclease/exonuclease/phosphatase
family domain-containing-1 (EEPD1)/radiation repair protein 52 (RAD52) with or without X-ray repair cross-complementing protein (XRCC4),
DNA ligase IV (LIG4) or polymerase theta (POLQ) siRNA for 48 h and cells were plated for colony formation survival assays. a Western blot
analysis of EEPD1, RAD52, XRCC4, LIG4, and POLQ protein expression with cyclophilin B (CypB) as a loading control in the transfected
BRCA1-/- cancer cells. b Representative images of clonal colonies from each condition after 14 days. c Quantitative analysis of colony formation that
targeted the classical non-homologous end-joining (cNHEJ) pathway or aNHEJ pathway. Each experiment was performed more than three distinct
times in triplicate (*p < 0.05, **p < 0.01, ***p < 0.001)
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We had previously shown that EEPD1 actively re-
presses aNHEJ while promoting HR, consistent with
this hypothesis [41].
There are several other lines of evidence that endonu-
cleases mediate stressed replication fork collapse and cell
death if fork repair is not completed in a timely manner.
For example, BRCA2 protects stressed replication forks
from degradation by the nuclease Mre11 [41], perhaps
by promoting timely loading of RAD51 onto end
resected 3′ SS DNA [55, 56]. In BRCA2 mutant cells,
the histone H3 lysine 4 methylase (MLL3/4) complex
component Pax transcription activation domain inter-
action protein 1-like protein (PTIP) was found to recruit
double-strand break repair nuclease (Mre11) to stalled
replication forks, causing degradation of nascent DNA
strands [57]. The Werner’s syndrome helicase (WRN)
also stabilizes stressed replication forks and prevents
their destruction by Mre11 [48]. WRN interacting pro-
tein1 (WRNIP1) stabilizes RAD51 on 3′ end-resected SS
DNA, and prevents prolonged and excessive end resec-
tion by Mre11, thereby protecting stressed replication
forks from degradation [49]. Finally, bi-orientation defect
1-like (BOD1L), a large protein with N-terminal hom-
ology to the mitotic regulator BOD1, is recruited to
stressed replication forks where it stabilizes RAD51 on
the 3′ SS end-resected DNA, which blocks further
Bloom syndrome recQ-like helicase (BLM) unwinding
and DNA2-mediated end resection [50]. In each of these
examples, excessive nuclease degradation of stressed
replication forks is prevented by proteins recruited to
stressed forks to regulate end resection. These reports
demonstrating that sophisticated mechanisms have
evolved to protect excessive degradation of stressed
forks provides further evidence that such repair interme-
diates are toxic to the cell.
There is a significant effort to create small molecular in-
hibitors of RAD52 in order to clinically treat BRCA1 and
BRCA2 mutant breast and ovarian cancers [26, 38–40, 51].
Inhibition of RAD52 might be epistatic with PARP1 inhib-
ition, since both strategies rely on the failure of replication
fork repair and restart for their lethal effects, albeit at dis-
tinct steps in that pathway. Thus, combining PARP1 and
RAD52 inhibitors to treat BRCA1 or BRCA2 mutant can-
cers might provide little or no therapeutic gain, and might
increase normal tissue toxicity. Synthetic lethality from ei-
ther PARP1 or RAD52 inhibition involves toxic replication
fork repair intermediates that generate mitotic catastrophe
and cell death [26, 29, 52, 53]. Given that depleting EEPD1
prevents synthetic lethality of RAD52 repression in BRCA1
mutant cancer cells, potential mechanisms by which cancer
cells could become resistant to clinically useful RAD52 in-
hibitors are by repressing EEPD1 expression or acquiring
EEPD1 loss-of-function mutations [52]. Either of these
mechanisms would shunt stressed replication fork repair to
aNHEJ [55–57]. Thus, EEPD1 could be used as a bio-
marker for treatments that target RAD52 in BRCA1/2
mutant cancers.
Conclusion
The mechanism by which RAD52 depletion causes syn-
thetic lethality in BRCA1 mutant cancer cells depends
on the 5′ endonuclease EEPD1, which normally func-
tions to cleave stressed replication forks to initiate HR
repair. Such cells face death because these cleaved forks
cannot complete repair when both BRCA1/2-mediated
HR and the RAD52 backup pathway are impaired.
Additional files
Additional file 1: Figure S1. RAD52 depletion does not induce synthetic
lethality in BRCA1-replete breast cancer cells. a–c MDA-MB-436 cells with
intact BRCA1 transduced back were transfected with control or RAD52
siRNA for 48 h and then cells were plated for colony formation survival
assays. a Western blot analysis of RAD52 depletion. b Representation images
of CFUs from each condition after 12 days. c Quantitative analysis of colony
formation. (d–f) MDA-MB-436 BRCA1+ cells were transiently transfected with
control or RAD52 siRNA, with or without BRCA1 siRNA, for 48 h. Cells were
plated for colony formation survival assays. d Western blot analysis of
RAD52 and BRCA1 depletion. e Representation images of CFUs from each
condition after 12 days. f Quantitative analysis of colony formation. Each
experiment was performed≥ 3 distinct times in triplicate. (PDF 456 kb)
Additional file 2: Figure S2. EEPD1 depletion in SUM149PT BRCA1
mutant breast cancer cells rescues synthetic lethality from RAD52
depletion. a–c SUM149PT BRCA1-/- cells were transiently transfected
with control or RAD52 siRNA for 48 h and cells were plated for
colony formation survival assays. a Western blot analysis of RAD52
and EEPD1 depletion. b Representation images of CFUs from each
condition after 12 d. c Quantitative analysis of colony formation. Each
experiment was performed ≥ 3 distinct times in triplicate.
(PDF 263 kb)
Additional file 3: Figure S3. EEPD1 depletion in BRCA1-depleted MCF7
breast cancer cells rescues synthetic lethality from RAD52 depletion. a–c
MCF7 BRCA1-proficient cells were transiently transfected with control or
RAD52 siRNA, with or without BRCA1 siRNA, for 48 h. Cells were plated for
colony formation survival assays. a Western blot analysis. b Representation
images of CFUs from each condition after 14 days. c Quantitative analysis of
colony formation. d–f MCF7 BRCA1-proficient cells were transiently trans-
fected with control, EEPD1 and/or RAD52 siRNA, with BRCA1 siRNA, for 48 h.
Cells were plated for colony formation survival assays. d Western blot
analysis. e Representation images of CFUs from each condition after
14 days. f Quantitative analysis of colony formation. Each experiment
was performed ≥ 3 distinct times in triplicate. (PDF 459 kb)
Additional file 4: Figure S4. Single-label DNA fiber analysis of stressed
replication fork degradation. MDA-MB-436 BRCA1-/- cells were transiently
transfected with control, EEPD1 and/or RAD52 siRNA for 48 h and labeled
with IdU for 45 min before proceeding to either 0 h or 10 h incubation
with 5 mM HU. DNA degradation at stalled nascent replication forks was
measured by fiber analysis. a Schematic diagram depicts steps for the
DNA fiber assay and representative images of DNA fibers from each condition.
IdU stained red (stalled forks). Quantitative analysis of IdU track length
frequency at unstressed (no HU) (b), or HU-treated DNA fibers (c) from
each condition. d Bar chart from the HU-treated IdU track length
frequencies analysis. c and d are the same data. Co-depletion of both
RAD52 and EEPD1 restores stressed replication fork degradation back
to control levels. Three distinct experiments per condition (>100 fibers
measured per condition for each experiment). (PDF 419 kb)
Additional file 5: Figure S5. cNHEJ DNA repair pathway is nonessential
for MDA-MB-436 BRCA1 mutant breast cancer cells to survive. a–c MDA-MB-
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436 BRCA1-/- cells were transfected with control or XRCC4 siRNA for 48 h
and cells were plated for colony formation survival assays. a Western blot
analysis of XRCC4 depletion. b Representation images of CFUs from each
condition after 14 days. c Quantitative analysis of colony formation. d–f
MDA-MB-436 BRCA1-/- cells were transfected with control or LIG4 siRNA for
48 h and cells were plated for colony formation survival assays. d Western
blot analysis of XRCC4 depletion. e Representation images of CFUs from
each condition after 14 days. f Quantitative analysis of colony formation.
g–i MDA-MB-436 BRCA1-/- cells were transfected with control or POLQ
siRNA for 48 h and cells were plated for colony formation survival assays.
g Western blot analysis of POLQ depletion. h Representation images of
CFUs from each condition after 14 days. i Quantitative analysis of colony
formation. Each experiment was performed≥ 3 distinct times in triplicate.
(PDF 580 kb)
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